The disease affects approximately 1 million adults in the United States, according to the National MS Society, with varying clinical presentations including relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS)
Injection site selection: For systemic effects, standard abdominal subcutaneous injection works well
Atiq M, Holt AF, Safdar K, Weber F, Ravinuthala R, Jonas ME, Neff GW
LOUISVILLE, Ky
Guo, C., Huang, T., Chen, A., Chen, X., Wang, L., Shen, F., & Gu, X
Conclusion: Competition Is Shifting Toward Supply Chain Capability Retatrutide Phase III success is likely just the beginning, and may represent an early signal of how retatrutide reshape global peptide API demand in the next stage of industry evolution